TMS Network Activity Modeling for Healthy Subjects
Trial Summary
Will I have to stop taking my current medications?
The trial excludes participants who are on medications that influence brain function, so you may need to stop taking such medications to participate.
What data supports the effectiveness of the treatment Paired associative stimulation (PAS) and Single-pulse TMS (spTMS)?
Research shows that transcranial magnetic stimulation (TMS) can change brain activity and behavior, but its effects vary across different brain regions and individuals. This suggests that TMS, including its use in paired associative stimulation (PAS), may be effective in modulating brain networks, although individual responses can differ.12345
Is transcranial magnetic stimulation (TMS) generally safe for humans?
How does the treatment Paired associative stimulation (PAS) and Single-pulse TMS (spTMS) differ from other treatments?
Paired associative stimulation (PAS) and Single-pulse TMS (spTMS) are unique because they use magnetic fields to stimulate specific brain areas, potentially altering brain network activity and connectivity. This approach is different from traditional treatments that might rely on medication or other forms of therapy, as it directly targets brain function and connectivity, which could lead to more personalized treatment strategies.1391011
What is the purpose of this trial?
This is a study of normal brain physiology in healthy human volunteers. The study aims to understand the physiology of connectivity between brain regions. To reach this aim, it delivers single-pulse transcranial magnetic stimulation (spTMS) to one or two brain areas at a time while electroencephalography (EEG) is measured. When only one brain area is stimulated (uni-focal TMS), the goal is to record how many milliseconds it takes for the activity to spread from the stimulated area to other brain regions (conduction delay). When two brain areas are stimulated (bi-focal TMS), the TMS pulses are separated by a short millisecond-level time interval ("asynchrony") in a so-called paired associative stimulation (PAS) design. The central hypothesis is that PAS may increase or decrease connectivity between the stimulated areas depending on the asynchrony value. All techniques in the study are non-invasive and considered safe.
Research Team
Aapo Nummenmaa, PhD
Principal Investigator
Mass General Brigham
Eligibility Criteria
This trial is for healthy individuals with normal hearing and vision (corrected if necessary) who can understand and consent to participate. It's not suitable for those with metal in their body, heart devices, neurological or psychiatric conditions affecting brain function, developmental disorders, seizure history, substance abuse issues, pregnancy or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
MRI Scanning
Participants undergo MRI scans including T1-weighted, T2-weighted, diffusion MRI, and resting-state fMRI
Uni-focal TMS Session
Participants receive uni-focal TMS to various cortical targets while EEG is recorded to determine inter-regional conduction delays
Bi-focal TMS Sessions
Participants undergo bi-focal TMS (PAS) sessions with different asynchronies to assess connectivity changes
Follow-up
Participants are monitored for safety and effectiveness after the TMS sessions
Treatment Details
Interventions
- Paired associative stimulation (PAS)
- Single-pulse TMS (spTMS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor